会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS
    • 含有双相类型化合物的药物组合物
    • WO1994013657A1
    • 1994-06-23
    • PCT/GB1993002513
    • 1993-12-08
    • SMITHKLINE BEECHAM PLCSMITHKLINE BEECHAM CORPORATIONCHAN, Wai, NgorEVANS, John, MorrisSTEMP, GeoffreyUPTON, NeilWILLETTE, Robert, Nicholas
    • SMITHKLINE BEECHAM PLCSMITHKLINE BEECHAM CORPORATION
    • C07D311/68
    • C07D409/06C07D311/68C07D409/12
    • A compound of formula (I) or pharmaceutically acceptable salt thereof wherein: either Y is N and R2 is hydrogen, or Y is C-R1 where: either one of R1 and R2 is hydrogen and the other is selected from the class of hydrogen, C3-8 cycloalkyl, C1-6 alkyl optionally interrupted by oxygen or substituted by hydroxy, C1-6 alkoxy or substituted aminocarbonyl, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkoxy, nitro, cyano, halo, trifluoromethyl, CF3S, or a group CF3-A-, where A is -CF2-, -CO-, -CH2-, CH(OH), SO2, SO, CH2-O, or CONH, or a group CF2H-A'- where A' is oxygen, sulphur, SO, SO2, CF2 or CFH; trifluoromethoxy, C1-6 alkylsulphinyl, perfluoro C2-6 alkylsulphonyl, C1-6 alkylsulphonyl, C1-6 alkoxysulphinyl, C1-6 alkoxysulphonyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, phosphono, arylcarbonyloxy, heteroarylcarbonyloxy, arylsulphinyl, heteroarylsulphinyl, arylsulphonyl, heteroarylsulphonyl in which any aromatic moiety is optionally substituted, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, C1-6 alkyl-thiocarbonyl, C1-6 alkoxy-thiocarbonyl, C1-6 alkyl-thiocarbonyloxy, 1-mercapto C2-7 alkyl, formyl, or aminosulphinyl, aminosulphonyl or aminocarbonyl, any amino moiety being optionally substituted by one or two C1-6 alkyl groups, or C1-6 alkylsulphinylamino, C1-6 alkylsulphonylamino, C1-6 alkoxysulphinylamino or C1-6 alkoxysulphonylamino, or ethylenyl terminally substituted by C1-6 alkylcarbonyl, nitro or cyano, or -C(C1-6 alkyl)NOH or -C(C1-6 alkyl)NNH2, or one of R1 and R2 is nitro, cyano or C1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C1-6 alkyl or by C2-7 alkanoyl; or R1 and R2 together are -(CH2)4- or -CH CH-CH CH-, or form an optionally substituted triazole or oxadiazole ring; and X is oxygen or NR10 where R10 is hydrogen or C1-6 alkyl with the proviso that the compound is not racemic cis-4-benzoylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol.
    • 式(I)化合物或其药学上可接受的盐,其中:Y是N,R2是氢,或Y是C-R1,其中:R1和R2中的任一个是氢,另一个选自氢, C 3-6烷氧基,C 1-6烷氧基,硝基,氰基,C 1-6烷基, 卤素,三氟甲基,CF 3 S或基团CF 3 -A,其中A是-CF 2 - , - CO - , - CH 2 - ,CH(OH),SO 2,SO,CH 2 -O或CONH,或CF 2 H- A'-其中A'为氧,硫,SO,SO2,CF2或CFH; 三氟甲氧基,C 1-6烷基亚磺酰基,全氟C 2-6烷基磺酰基,C 1-6烷基磺酰基,C 1-6烷氧基亚磺酰基,C 1-6烷氧基磺酰基,芳基,杂芳基,芳基羰基,杂芳基羰基,膦酰基,芳基羰基氧基,杂芳基羰氧基,芳基亚磺酰基,杂芳基亚磺酰基,芳基磺酰基,杂芳基磺酰基 任何芳族部分任选被取代,C 1-6烷基羰基氨基,C 1-6烷氧基羰基氨基,C 1-6烷基 - 硫代羰基,C 1-6烷氧基 - 硫代羰基,C 1-6烷基 - 硫代羰基氧基,1-巯基C 2-7烷基,甲酰基或 氨基亚磺酰基,氨基磺酰基或氨基羰基,任选被一个或两个C 1-6烷基取代的氨基部分,或C 1-6烷基亚磺酰氨基,C 1-6烷基磺酰基氨基,C 1-6烷氧基亚磺酰氨基或C 1-6烷氧基磺酰基氨基,或被C 1 -C 6末端取代的亚乙基, 6烷基羰基,硝基或氰基或-C(C 1-6烷基)NOH或-C(C 1-6烷基)NNH 2,或R 1和R 2之一是硝基,氰基或C 1-3烷基羰基,另一个是甲氧基或氨基 可选地替代 d由一个或两个C 1-6烷基或C 2-7烷酰基取代; 或者R 1和R 2一起是 - (CH 2)4 - 或-CH 3 CH-CH,或形成任选取代的三唑或恶二唑环; 并且X是氧或NR 10,其中R 10是氢或C 1-6烷基,条件是该化合物不是外消旋的顺式-4-苯甲酰基氨基-6-氰基-3,4-二氢-2,2-二甲基-2H-苯并[ b]吡喃-3-醇。
    • 6. 发明申请
    • N-ARYL ACETYL CYCLIC AMINE DERIVATIVES AS OREXIN ANTAGONISTS
    • N-ARYL ACETYL循环胺衍生物作为OREXIN ANTAGONISTS
    • WO2004041791A1
    • 2004-05-21
    • PCT/EP2003/012407
    • 2003-11-04
    • GLAXO GROUP LIMITEDCHAN, Wai, NgorNASH, David, JohnPORTER, Roderick, AlanSTEAD, Rachel, Elizabeth, Anne
    • CHAN, Wai, NgorNASH, David, JohnPORTER, Roderick, AlanSTEAD, Rachel, Elizabeth, Anne
    • C07D241/44
    • C07D401/12C07D405/14
    • The present invention provides N -aryl acetyl cyclic amine derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors. In particular, theses compounds are of potential use in the treatment of obesity, including obesity observed in Type 2 (non-insulin-dependent) diabetes patients, and/or sleep disorders. Additionally these compounds are useful in the treatment of stroke, particularly ischemic or haemorrhagic stroke, and/or blocking the emetic response, i.e. useful in the treatment of nausea and vomiting. (I) wherein: Y represents a bond, oxygen, NQ or a group (CH 2 ) n , wherein n represents 1, 2 or 3 m is 0 or 1; X is NR, wherein R is H or (C 1-4 )alkyl; Q is H or (C 1-4 )alkyl; Ar 1 is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; any of which may be optionally substituted; Ar 2 represents optionally substituted phenyl, an optionally substituted 5- or 6- membered heterocyclyl group containing up to 4 heteroatoms selected from N, O and S, or an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 4 heteroatoms selected from N, O and S; R 1 and R 2 independently represent hydrogen, optionally substituted amino, optionally substituted (C 1-6 )alkyl or optionally substituted phenyl; or a pharmaceutically acceptable salt thereof.
    • 本发明提供作为人食欲素受体的非肽拮抗剂的N-芳基乙酰基环胺衍生物,特别是食欲素-1受体。 特别地,这些化合物可用于治疗肥胖症,包括在2型(非胰岛素依赖性)糖尿病患者中观察到的肥胖症和/或睡眠障碍。 另外,这些化合物可用于治疗中风,特别是缺血性或出血性中风,和/或阻断催吐反应,即可用于治疗恶心和呕吐。 (I)其中:Y表示键,氧,NQ或基团(CH 2)n,其中n表示1,2或3m为0或1; X是NR,其中R是H或(C 1-4)烷基; Q是H或(C 1-4)烷基; Ar 1是芳基或含有至多4个选自N,O和S的杂原子的单或双环杂芳基; 任何一个可以任选地被取代; Ar 2表示任选取代的苯基,任选取代的含有至多4个选自N,O和S的杂原子的5-或6-元杂环基,或含有至多4个选自以下的杂原子的任选取代的双环芳族或双环杂芳族基团: N,O和S; R 1和R 2独立地表示氢,任选取代的氨基,任选取代的(C 1-6)烷基或任选取代的苯基; 或其药学上可接受的盐。
    • 7. 发明申请
    • BICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY
    • 具有药物活性的双环化合物
    • WO1994013656A1
    • 1994-06-23
    • PCT/GB1993002512
    • 1993-12-08
    • SMITHKLINE BEECHAM PLCSMITHKLINE BEECHAM CORPORATIONTHOMPSON, MervynEVANS, John, MorrisUPTON, NeilCHAN, Wai, NgorVONG, Kuok, KeongWILLETTE, Robert, Nicholas
    • SMITHKLINE BEECHAM PLCSMITHKLINE BEECHAM CORPORATION
    • C07D311/68
    • C07D405/12C07D311/68C07D407/12C07D409/12
    • A method of treatment and/or prophylaxis of disorders resulting from subarachnoid haemorrhage, neural shock, cerebral ischaemia, Parkinson's Disease, migraine and/or psychosis, in mammals, especially humans which comprises administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I) or pharmaceutically acceptable salt thereof, wherein either Y is N and R2 is hydrogen, or Y is C-R1 where either one of R1 and R2 is hydrogen and the other is selected from the class of hydrogen, C3-8 cycloalkyl, C1-6 alkyl optionally interrupted by oxygen or substituted by hydroxy, C1-6 alkoxy or substituted aminocarbonyl, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkoxy, nitro, cyano, halo, trifluoromethyl, CF3S, or a group CF3-A-, or a group CF2H-A'-; trifluoromethoxy, C1-6 alkylsulphinyl, perfluoro C2-6 alkylsulphonyl, C1-6 alkylsulphonyl, C1-6 alkoxysulphinyl, C1-6 alkoxysulphonyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, phosphono, arylcarbonyloxy, heteroarylcarbonyloxy, arylsulphinyl, heteroarylsulphinyl, arylsulphonyl, heteroarylsulphonyl in which any aromatic moiety is optionally substituted, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, C1-6 alkyl-thiocarbonyl, C1-6 alkoxy-thiocarbonyl, C1-6 alkyl-thiocarbonyloxy, 1-mercapto C2-7 alkyl, formyl, or aminosulphinyl, aminosulphonyl or aminocarbonyl, any amino moiety being optionally substituted by one or two C1-6 alkyl groups, or C1-6 alkylsulphinylamino, C1-6 alkylsulphonylamino, C1-6 alkoxysulphinylamino or C1-6 alkoxysulphonylamino, or ethylenyl terminally substituted by C1-6 alkylcarbonyl, nitro or cyano, or -C(C1-6 alkyl)NOH or -C(C1-6 alkyl)NNH2, or one of R1 and R2 is nitro, cyano or C1-3 alkylcarbonyl and the other is methoxy or amino group; or R1 and R2 together are -(CH2)4- or -CH CH-CH CH-, or form an optionally substituted triazole or oxadiazole ring; and X is oxygen or NR10.
    • 一种治疗和/或预防哺乳动物,特别是人的蛛网膜下腔出血,神经性休克,脑局部缺血,帕金森病,偏头痛和/或精神病引起的疾病的方法,包括向有需要的患者施用有效或预防量的 式(I)化合物或其药学上可接受的盐,其中Y为N且R 2为氢,或Y为C-R 1,其中R 1和R 2中的任一个为氢,另一个选自氢,C 3 -8环烷基,任选被氧中断或被羟基取代的C 1-6烷基,C 1-6烷氧基或取代的氨基羰基,C 1-6烷基羰基,C 1-6烷氧基羰基,C 1-6烷基羰氧基,C 1-6烷氧基,硝基,氰基,卤素 ,三氟甲基,CF 3 S或CF 3 -A-或CF 2 H-A'-基团; 三氟甲氧基,C 1-6烷基亚磺酰基,全氟C 2-6烷基磺酰基,C 1-6烷基磺酰基,C 1-6烷氧基亚磺酰基,C 1-6烷氧基磺酰基,芳基,杂芳基,芳基羰基,杂芳基羰基,膦酰基,芳基羰基氧基,杂芳基羰氧基,芳基亚磺酰基,杂芳基亚磺酰基,芳基磺酰基,杂芳基磺酰基 任何芳族部分任选被取代,C 1-6烷基羰基氨基,C 1-6烷氧基羰基氨基,C 1-6烷基 - 硫代羰基,C 1-6烷氧基 - 硫代羰基,C 1-6烷基 - 硫代羰基氧基,1-巯基C 2-7烷基,甲酰基或 氨基亚磺酰基,氨基磺酰基或氨基羰基,任选被一个或两个C 1-6烷基取代的氨基部分,或C 1-6烷基亚磺酰氨基,C 1-6烷基磺酰基氨基,C 1-6烷氧基亚磺酰氨基或C 1-6烷氧基磺酰基氨基,或被C 1 -C 6末端取代的亚乙基, 6烷基羰基,硝基或氰基或-C(C 1-6烷基)NOH或-C(C 1-6烷基)NNH 2,或R 1和R 2之一是硝基,氰基或C 1-3烷基羰基,另一个是甲氧基或氨基 组; 或者R 1和R 2一起是 - (CH 2)4 - 或-CH 3 CH-CH,或形成任选取代的三唑或恶二唑环; X是氧或NR 10。